Projects per year
Fingerprint
Dive into the research topics where Jens Tijtgat is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 1 Active
-
A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors
Awada, G., Schwarze, J. K., Tijtgat, J., Fasolino, G., Kruse, V. & Neyns, B., 2022, In : Melanoma Research. 32, 3, p. 183-191 9 p.Research output: Contribution to journal › Article
-
Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial
Schwarze, J. K., Garaud, S., Jansen, Y., Awada, G., Vandersleyen, V., Tijtgat, J., de Wind, A., Kristanto, P., Seremet, T., Willard-Gallo, K. & Neyns, B., Feb 2022, In : Cancers (Basel). 14, 3, 22 p., 682.Research output: Contribution to journal › Article
Open Access -
371P - Low-dose bevacizumab for the treatment of focal post-radiation necrosis of the brain
Tijtgat, J., Schwarze, J. K. & Awada, G., 16 Sep 2021.Research output: Unpublished contribution to conference › Poster
-
Abstract 962MO. A phase I clinical trial on intratumoral injection of autologous CD1C (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells (myDC) in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Schwarze, J. K., Tijtgat, J., Awada, G., Cras, L., Dufait, I., Forsyth, R., Van Riet, I., Tuyaerts, S. & Neyns, B., 1 Sep 2021, In : Annals of Oncology. 32, p. S832-S833Research output: Contribution to journal › Meeting abstract (Journal)
-
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab
Awada, G., Jansen, Y., Schwarze, J. K., Tijtgat, J., Hellinckx, L., Gondry, O., Vermeulen, S., Warren, S., Schats, K., van Dam, P-J., Kockx, M., Keyaerts, M., Everaert, H., Seremet, T., Rogiers, A. & Neyns, B., 2 Jan 2021, In : Cancers. 13, 2, p. 1-18 18 p., 168.Research output: Contribution to journal › Article
Open Access7 Citations (Scopus)
Activities
- 2 Talk or presentation at a conference
-
A phase Ib/II clinical trial on intratumoral autologous myeloid dendritic cell therapy in combination with AS01B adjuvant and immune-checkpoint blockade
Jens Tijtgat (Speaker)19 May 2022Activity: Talk or presentation › Talk or presentation at a conference
-
A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Julia Katharina Schwarze (Presenter), Jens Tijtgat (Contributor), Gil Awada (Contributor), Louise Cras (Contributor), Inès Dufait (Contributor), Ramses Forsyth (Contributor), Sandra Tuyaerts (Contributor), Bart Neyns (Contributor)17 Sep 2021Activity: Talk or presentation › Talk or presentation at a conference
Thesis
-
IMMUNOGENIC CELL DEATH IN ONCOLYTIC VIROTHERAPY: T-VEC in the treatment of cutaneous melanoma
Author: Tijtgat, J., 2019Student thesis: Master's Thesis